Evidence map›Paper›PMID 35070763›Full record

ArticleTranslational lung cancer research2021

A standard for hilar and intrapulmonary lymph node dissection and pathological examination in early non-small cell lung cancer.

Zhihua Zhu, Weijian Mei, Zhengbo Song, Wenjie Jiao, Qinghua Huang, Lianxin Zhu, Chaolun An, Jianguang Shi, Wenxian Wang, Guiping Yu and 12 more

Open access · diamondAbstract read
In one paragraph

Article in Translational lung cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Applications of circulating tumor DNA in unresectable and advanced non-small cell lung cancer immunotherapy: from stratification to therapeutic guidance.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 6 institutions in 3 countries.

Zhihua Zhu *Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Weijian Mei *Department of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Zhengbo Song *Department of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Wenjie Jiao *Department of Thoracic Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
Qinghua Huang *Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China.
Lianxin Zhu *Medical College of Nanchang University, Nanchang, China.
Chaolun AnDepartment of Thoracic Surgery, Nantong Third People's Hospital Nantong University, Nantong, China.
Jianguang ShiDepartment of Thoracic Surgery, Ningbo First Hospital of Zhejiang University, Ningbo, China.
Wenxian WangDepartment of Medical Oncology, Cancer Hospital of University of Chinese Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, China.
Guiping YuDepartment of Thoracic Surgery, Affiliated Jiangyin Hospital of Southeast University, Jiangyin, China.
Pingli SunDepartment of Pathology, The Second Hospital of Jilin University, Changchun, China.
Yinbin ZhangDepartment of Thoracic Surgery, The Second Affiliated Hospital of Medical College, Xi'an Jiaotong University, Xi'an, China.
Jianfei ShenDepartment of Thoracic Surgery, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Taizhou, China.
Yong SongDepartment of Respiratory Medicine,, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Sebastien GilbertDivision of Thoracic Surgery, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.
Kurt RuetzlerDepartments of Outcomes Research and General Anesthesia, Anesthesiology Institute, Cleveland Clinic, Cleveland, OH, USA.
Nestor R VillamizarSection of Thoracic Surgery, Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA.
Chunwei XuDepartment of Respiratory Medicine,, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Jun QianDepartment of Statistics, Southern Medical University, Guangzhou, China.
Wang YaoDepartment of Interventional Oncology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Han YangDepartment of Thoracic Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
written on behalf of AME Lung Cancer Collaborative Group
Sun Yat-sen University · CNQingdao University · CNNanchang University · CNZhejiang Cancer Hospital · CNCleveland Clinic · USNantong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere is considerable variation in the staging of lymph nodes (LNs) as part of tumor, node, metastasis (TNM) staging of non-small cell lung cancer (NSCLC). A new dissection and pathological examination standard for hilar and intrapulmonary LNs needs to be established for patients with early-stage T1-3N0M0 NSCLC.

methodsThis study involved 3,002 patients with T1-3N0M0 NSCLC who underwent radical lobectomy or total pneumonectomy in the thoracic departments of 11 Chinese institutions between January 1999 and October 2013. The Cox model was applied for univariate and multivariate analyses in the examination of station 10, 11 LN and station 12, 13, 14 LN. A hilar and intrapulmonary standard (HI standard) was then established based on univariate and multiple-factor analyses conducted using the Cox model.

resultsAmong the 3,002 patients enrolled in the study, 2,609 underwent at least one examination of station 10, 11 LN (A1), while 393 did not undergo examination of station 10, 11 LN (A0). The A0 and A1 groups had 5-year survival rates of 76% and 80%, respectively (P=0.018). Further, 1,764 patients underwent at least one examination of station 12, 13, 14 LN (B1), while 1,238 patients did not (B0). The B0 and B1 groups had 5-year survival rates of 77% and 82%, respectively (P=0.008). In total, 1,269 patients attained the HI standard (C1), and 1,733 did not (C0). The C0 and C1 groups had 5-year survival rates of 77% and 83%, respectively (P<0.001).

conclusionsThe HI standard can improve both the prognosis and survival rates of patients with T1-3N0M0 NSCLC. This will provide important guidance for pulmonary LN dissection and pathological examination in NSCLC cases.

Indexed as

early stagelymph node dissection (LN dissection)Non-small cell lung cancer (NSCLC)pathological examination standard

Identifiers

PMID35070763
PMCPMC8743510
OpenAlexW4206477120

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.